ImmunoGen is poised to solve a major unmet medical need in ovarian cancer


On January 26, 2017, ImmunoGen announced that the first patient was dosed in its pivotal Phase III study that investigates mirvetuximab soravtansine as a single agent treatment in ovarian cancer, thereby positioning its novel antibody-drug conjugate (ADC) well within the late-stage pipeline. If ImmunoGen can replicate the early results first presented at ASCO 2016, it has the potential to solve a major unmet medical need for patients with platinum-resistant disease.

Once a patient becomes resistant to platinum-based chemotherapy regimens, the efficacy and duration of response with current treatment options are highly limited and demonstrate modest activity at best. The FORWARD I study aims to recruit 333 ovarian cancer patients and randomize them 2:1 to receive either mirvetuximab soravtansine or the physician’s choice of single-agent chemotherapy (pegylated liposomal doxorubicin, toptotecan, or weekly paclitaxel). The primary endpoint of progression-free survival (PFS) will be assessed in the entire study population and in the subset of patients with high folate receptor alpha (FRA) expression.

ImmunoGen demonstrated encouraging single agent activity in 46 platinum-resistant ovarian cancer patients

At ASCO 2016, ImmunoGen demonstrated encouraging single agent activity in 46 platinum-resistant ovarian cancer patients, with a confirmed objective response rate (ORR) of 26% with 1 complete response (CR) and 11 partial responses (PRs), a median PFS of 4.8 months, and a median duration of response (DOR) of 19.1 weeks. The experimental treatment was well tolerated and 28% of patients required dose modifications due to low grade ocular adverse events (AEs). These eye-related toxicity concerns decreased in patients enrolled in the latter part of the study, which was attributed to more effective management procedures. Most importantly, in a subgroup analysis of 16 patients with one to three prior lines of therapy with medium to high folate receptor alpha expression, ImmunoGen saw a 44% ORR, a median PFS of 6.7 months, and a median DOR of 26.1 weeks.

GlobalData’s primary research has confirmed that the response rate of 44% in this ovarian cancer patient segment is unprecedented, especially with single-agent activity. The company has therefore designed its Phase III FORWARD I study to enroll patients with platinum-resistant ovarian cancer with one to three prior therapies with medium or high levels of FRA expression.

The response rate of 44% in this ovarian cancer patient segment is unprecedented, especially with single-agent activity

Mirvetuximab soravtansine is an antibody-drug conjugate that selectively targets cells that express FRA and delivers its cytotoxic payload, DM4, to kill cells. Unlike previous FRA antibodies, like Morphotek’s farletuzumab, Immunogen’s asset doesn’t solely rely on the patient’s immune system to kill cancer cells.  This small nuance is important, especially in heavily pre-treated patients whose immune systems can be compromised due to previous drug treatments and their overall health status. Furthermore, the FRA pathway is not important for ovarian cancer cell survival, so even if it is blocked, the cancer still grows. Key opinion leaders (KOLs) interviewed by GlobalData say this is a major differentiator for mirvetuximab soravtansine, and the question now becomes: how much FRA expression is necessary in order for it to become a valuable target for a precision medicine treatment?

ImmunoGen’s long-term growth prospects in the ovarian cancer space are bolstered by early stage investigations looking to improve single agent mirvetuximab soravtansine’s activity by combining it with Roche/Genentech’s approved ovarian cancer angiogenesis inhibitor, Avastin (bevacizumab); Merck and Co.’s immune checkpoint inhibitor blockbuster Keytruda (pembrolizumab); the first-line standard of care chemotherapy carboplatin; and pegylated liposomal doxorubicin. These are the combinations being investigated in the ongoing Phase Ib/II FORWARD II trial. Their anticipated increased efficacy compared to the single agent regimen and current standards of care could firmly entrench mirvetuximab soravtansine earlier in the treatment paradigm, especially if the combinations are well tolerated. ImmunoGen has a lot of work ahead, but the future is bright for its novel ADC, which could simultaneously solve a major problem for platinum-resistant recurrent ovarian cancer patients and represent a major victory for the precision medicine movement.

Related Report

Immuno-Oncology Strategic Insight: Multi-Indication and Market Size Analysis
GlobalData estimates that the total IO market will be worth approximately $14 billion in 2019, rising to $34 billion by 2024 in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan). The main drivers of this growth will come from immune checkpoint inhibitors, which will have sales of approximately $10 billion in 2019, rising to $24 billion by 2024.